Allergy or Allergic rhinitis is caused by sensitivity to a number of environmental factors including grass, tree and weed pollens, housedust mite and cat dander. Prevalence in adults can range from 17 – 40% and is region/climate dependent. For those patients failingto respond to symptomatic treatments e.g. antihistamines Allergen-specific immunotherapy can be an effective alternative whichinvolves long term treatment with SLIT or SCIT based products.
Current market leaders in Allergen-specific immunotherapies are ALK-Abello (Denmark) and Stallergenes (France) which arecurrently focused on both global expansion strategies for their existing products e.g. Grazax/Oralair but also new productdevelopment to address the major unmet need of a more convenient administration profile(s).
This MarketVIEW product is a comprehensive commercial opportunity assessment detailing the current market for Allergen-specificimmunotherapies with a patient based value/volume forecast for all relevant allergens/administration routes to 2030. The model takesinto account significant future events including penetration into new countries/regions and launch of new products. A discussion isalso included with regard to latest epidemiology; review of regulatory/reimbursement/pricing issues and a focus on key earlystage/late stage R&D development programs.